Ascendis Pharma to Present Hypoparathyroidism, Achondroplasia Program Updates
Ascendis Pharma A/S announced that recent advancements in its hypoparathyroidism and achondroplasia programs will be featured at the upcoming ASBMR 2026 annual meeting.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.